Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 36.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,142 shares of the medical research company's stock after acquiring an additional 8,542 shares during the period. Nisa Investment Advisors LLC's holdings in Natera were worth $4,545,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Axxcess Wealth Management LLC boosted its holdings in Natera by 119.1% in the 1st quarter. Axxcess Wealth Management LLC now owns 3,122 shares of the medical research company's stock valued at $441,000 after purchasing an additional 1,697 shares during the last quarter. Lee Johnson Capital Management LLC purchased a new position in shares of Natera in the 1st quarter worth $3,680,000. Ninety One UK Ltd purchased a new stake in shares of Natera during the first quarter worth about $31,959,000. Huntleigh Advisors Inc. grew its holdings in shares of Natera by 9.7% during the first quarter. Huntleigh Advisors Inc. now owns 10,027 shares of the medical research company's stock valued at $1,418,000 after purchasing an additional 890 shares during the last quarter. Finally, Calamos Advisors LLC boosted its position in shares of Natera by 29.0% during the first quarter. Calamos Advisors LLC now owns 29,637 shares of the medical research company's stock worth $4,191,000 after buying an additional 6,667 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on NTRA. UBS Group lifted their target price on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Piper Sandler upped their price target on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. Barclays upped their target price on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.07, for a total transaction of $471,210.00. Following the completion of the sale, the insider directly owned 133,205 shares in the company, valued at $20,922,509.35. This represents a 2.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 6,980 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $150.10, for a total transaction of $1,047,698.00. Following the transaction, the chief executive officer owned 185,182 shares in the company, valued at $27,795,818.20. This represents a 3.63% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,272 shares of company stock valued at $8,345,368. Corporate insiders own 7.60% of the company's stock.

Natera Trading Down 5.3%

Shares of Natera stock traded down $8.33 during midday trading on Tuesday, reaching $149.85. The company had a trading volume of 1,544,593 shares, compared to its average volume of 1,421,086. The stock has a fifty day simple moving average of $161.05 and a 200 day simple moving average of $158.41. The company has a market capitalization of $20.46 billion, a price-to-earnings ratio of -101.94 and a beta of 1.73. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same quarter in the prior year, the firm posted ($0.56) EPS. The firm's quarterly revenue was up 36.5% on a year-over-year basis. Sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.